Ikena Oncology

Ikena Oncology

Biotechnology Research

Boston, Massachusetts 9,798 followers

Patient-directed oncology therapies across pathways relevant in tumor and immune cells

About us

Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which enables us to target specific patient populations that we believe are most likely to respond to treatment with our product candidates. We have assembled an experienced and well-respected team of drug hunters, translational researchers, clinicians and entrepreneurs drawn from many of the largest innovators in biotechnology, supported by top-tier investors and partners, as well as world-class advisors, to advance and broaden our portfolio of novel, patient-directed oncology therapies.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Boston, Massachusetts
Type
Public Company
Founded
2016
Specialties
Targeted Oncology, cancer therapeutics development, small molecule drug design, cancer biology, and translational science and biomarkers

Locations

  • Primary

    645 Summer Street

    Suite 101

    Boston, Massachusetts 02210, US

    Get directions

Employees at Ikena Oncology

Updates

Similar pages

Browse jobs

Funding

Ikena Oncology 3 total rounds

Last Round

Post IPO equity

US$ 40.0M

See more info on crunchbase